Stockwatch: Oncology Dynamics Underscore Roche And AstraZeneca’s Contrasting Fortunes
Cancer Drug Sales Diverged In 2020 And Not Just Due To The Pandemic
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.
You may also be interested in...
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.
J&J’s bullish outlook for 2021, robust fourth quarter and frequent guidance revisions in uncertain times contrasted with Novartis’s reticence.